authors
- Laurie, SA
- Arnold, Andrew
- Gauthier, I
- Chen, E
- Goss, G
- Ellis, P
- Shepherd, FA
- Matthews, S
- Robertson, J
- Seymour, L
Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) plus paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- June 20, 2006
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal